Publicacións nas que colabora con Mónica Marazuela Azpiroz (41)

2024

  1. Consensus on criteria for acromegaly diagnosis and remission

    Pituitary, Vol. 27, Núm. 1, pp. 7-22

2023

  1. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

    Endocrine, Vol. 75, Núm. 2, pp. 525-536

  2. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  3. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

  2. Pasireotide in the Personalized Treatment of Acromegaly

    Frontiers in Endocrinology, Vol. 12

2020

  1. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update

    Journal of Clinical Endocrinology and Metabolism, Vol. 105, Núm. 4, pp. E937-E946

  2. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

  3. Lat-1 and glut-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors

    Cancers, Vol. 12, Núm. 10, pp. 1-18

  4. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

2018

  1. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529

  2. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

    Scientific Reports, Vol. 8, Núm. 1

  3. Expert document on management of acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437

2017

  1. Prevalence of acromegaly in patients with symptoms of sleep apnea

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la Endocrinología española por la medicina individualizada y la investigación traslacional

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 6, pp. 274-284

  2. Genetic Predictors of Response to Different Medical Therapies in Acromegaly

    Progress in Molecular Biology and Translational Science (Elsevier B.V.), pp. 85-114

  3. Long-term treatment with pegvisomant for acromegaly: A 10-year experience

    Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550

  4. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY

    Pituitary, Vol. 19, Núm. 2, pp. 127-137

  5. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408